Adipogenic gene variants in patients with HIV-associated lipodystrophy

Objectives Although highly active antiretroviral therapy (HAART) has been hugely beneficial in the treatment of HIV, HIV lipodystrophy (HIVLD) associated with HAART is a serious adverse effect, with long-term consequences including metabolic disturbances and an increased risk of atherosclerotic disease. Although HIVLD is clearly related to the drug regimen, individual susceptibility also plays a role. We hypothesized that variation in genes regulating adipogenesis, and in those implicated in inherited forms of lipodystrophy, may predispose to the development of HIVLD. Methods DNA samples were obtained from 180 HAART-treated HIV + patients: 124 with HIVLD (HIVLD+) and 56 without HIVLD (HIVLD -). Diagnosis of HIVLD was carried out by clinician's confirmation of patient self-report. High-throughput genotyping using Sequenom was used to screen 62 single nucleotide polymorphisms (SNPs) in eight genes involved in adipogenesis and inherited forms of lipodystrophy. Statistical analysis was performed using Haploview. Multivariate analysis (logistic regression) was used to identify independent predictors of HIVLD development in HAART-treated patients. Results SNPs in two adipogenesis regulators, LPIN1 and CEBP alpha, showed a significant association with HIVLD whereas a SNP in ZMPSTE24, a zinc metalloproteinase involved in prelamin A processing, showed a trend toward significance. Multivariate analysis identified time since HIV diagnosis (P = 0.001) and carriage of more than one associated allele (P = 0.008) to be the most significant independent predictors for the development of HIVLD. Conclusion Genetic variation in key regulators of adipogenesis could interfere with fat storage and metabolism contributing to the development of HIVLD in HAART-treated HIV patients. These results need replication in other cohorts. Pharmacogenetics and Genomics 21:76-83 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.